Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts

To determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18–75). The average ti...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2023-10, Vol.118 (4), p.462-471
Main Authors: Takagi, Erina, Terakura, Seitaro, Fujigaki, Hidetsugu, Okamoto, Akinao, Miyao, Kotaro, Sawa, Masashi, Morishita, Takanobu, Goto, Tatsunori, Ozawa, Yukiyasu, Nishida, Tetsuya, Fukushima, Nobuaki, Ozeki, Kazutaka, Hanajiri, Ryo, Saito, Kuniaki, Murata, Makoto, Tomita, Akihiro, Kiyoi, Hitoshi
Format: Article
Language:English
Subjects:
Allografts
Antibodies
Antibody response
COVID-19
Hematology
Hematopoietic stem cells
Immunization
Immunoglobulin M
Medicine
Medicine & Public Health
mRNA
Oncology
Original Article
Severe acute respiratory syndrome coronavirus 2
Stem cell transplantation
Stem cells
Transplantation
Transplants & implants
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18–75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5–15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-023-03648-1